ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO431

Urinary Calprotectin, Neutrophil Gelatinase Associated Lipocalin (NGAL), and KIM-1 in the Differentiation of Inflammatory vs. Noninflammatory CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Seibert, Felix S., University Hospital Marien Hospital Herne, Herne, Germany
  • Westhoff, Timm H., University Hospital Marien Hospital Herne, Herne, Germany

It has been demonstrated that urinary neutrophil gelatinase-associated lipocalin (NGAL) and calprotectin are helpful biomarkers in the differentiation of intrinsic and prerenal acute kidney injury. The present cross-sectional study investigates, whether urinary biomarkers are able to differentiate primarily inflammatory from non-inflammatory entities in chronic kidney disease (CKD).


Urinary calprotectin, NGAL and kidney injury molecule-1 (KIM-1) concentrations were assessed in a study population of 143 patients with stable CKD and 29 healthy controls. Stable renal function was defined as an eGFR fluctuation 5ml/min/1.73m2 in the past 12 months. Pyuria, metastatic carcinoma and renal transplantation were regarded as exclusion criteria. Diabetic nephropathy, hypertensive nephropathy, and polycystic kidney disease were categorized as “non-inflammatory renal diseases”, whereas glomerulonephritis and vasculitis were regarded as “inflammatory renal diseases”.


Urinary calprotectin and NGAL concentrations significantly differed between CKD and healthy controls (p<0.05 each), whereas KIM-1 concentrations did not (p=0.84). Urinary calprotectin concentrations were numerically highest in glomerulonephritis/vasculitis (155.7 ng/ml), NGAL concentrations in diabetic and hypertensive nephropathy (18741 pg/ml), and KIM-1 concentrations in polycystic kidney disease (1556 pg/ml). However, the three biomarkers did neither show significant differences in-between the individual entities, nor the two categories of inflammatory vs. non-inflammatory renal diseases (calprotectin 155.7 vs. 96.99 ng/ml; NGAL 14896 vs. 11977 pg/ml; KIM-1 1388 vs. 1009 ng/ml; p>0.05 each).


The urinary biomarkers calprotectin, NGAL and KIM-1 have no diagnostic value in the differentiation of inflammatory vs. non-inflammatory etiologies of CKD.